Skip to main content

Get Health Care
About
Giving
Find Faculty
Library
Rush U Portal
I am a...
Select from the list below to customize your experience: Select a new category

I am a:

Education
Looking to take the next step in your career? Rush University offers a wide range of education and training options, including nationally ranked academic programs.

Find a Program
- Colleges
- Quick Links
Admissions
Student Life
Experience what life is like at Rush University, and discover what our supportive learning community has to offer.

Learn More About Student Life
- About the Rush Experience
- Quick Links
Research
Rush researchers are leading efforts to cure disease and promote health equity — in Chicago and around the world.

Learn More About Research
- About Our Research
- Quick Links

Get Health Care
About
Giving
Find Faculty
Library
Rush U Portal
I am a...
Select from the list below to customize your experience: Select a new category

I am a:

Search RUSH University

Vaskar Das, PhD

Breadcrumb

Home
Vaskar Das, PhD

Home

Assistant Professor, Department of Anesthesiology

Rush Medical College

Assistant Professor, Department of Anesthesiology

Contact Information

Address: 1653 W. Congress Pkwy., Jelke 1499
Chicago, IL 60612
Phone:
(312) 942-7608
Fax:
(312) 942-8858
Email:
vaskar_das@rush.edu

Links

Print this Page

Off

PhD in Neuropharmacology, University of Queensland, Australia
Post Doctoral Training, Pain Plasticity Mechanism, University of Texas at Dallas, US
Post Doctoral Training, Acute and Chronic Pain, RUSH University Medical Center, Chicago, IL, US
Vaskar Das, PhD is currently working on National Institutes of Health-funded pain research as a co-investigator. His research has focused on new non-opioid treatments for acute and chronic pain by following the key energy sensor AMPK (adenosine mono-phosphate activated kinase) and the pain-relieving effect of the ketamine metabolite (2R,6R)-hydroxynorketamine.

His Cohn research will expand to assess the pain-relieving efficiency and mechanisms of AMPK activators in peripheral tissue injury pain. One immediate outcome of this research will be much-needed pharmacological understanding of AMPK activators for low back pain and post-surgical pain.
Vaskar Das, PhD's major research interest is the discovering and development of analgesic drugs as an alternative pain medication to replace opioids for treatment of chronic pain. Ameliorate of chronic pain is very difficult to treat with current medication. Some of the examples of such disease condition are osteoarthritis (OA), low back pain (disc degeneration diseases) and postherpetic neuralgic pain (PHN), which is often recalcitrant to existing analgesics. Hence, during the course of his postdoctoral and PhD research program, he established, and pharmacologically validated various pain model in rodent. Examples of such, acute and chronic pain models are: (i) postoperative pain model, (ii) complex regional pain syndrome (CRPS) model, (iii) low back pain (disc degeneration diseases) model, (iv) spared nerve injury (SNI) neuropathic pain model, (v) migraine pain model, (vi) osteoarthritis pain model in mice and (vii) optimized rat model of Varicella zoster virus (VZV)-induced neuropathic pain (postherpetic neuralgia) under the supervision of Prof. Asokumar Buvanendran, MD, Prof. Jeffrey S. Kroin, Prof. Robert J McCarthy (D-Pharm), Department of Anesthesiology, Rush University Medical Center and Prof. Maree Smith (CIPDD (Centre for Integrated Preclinical Drug Development) and School of Pharmacy, the University of Queensland (UQ).

He has invented a new device for the assessment of cold allodynia in the hind paws of rodent models of neuropathic pain that overcomes the limitations of currently available commercial devices. A prototype of that device is currently being built at the UQ Department of Physics workshop and it is ready for beta testing.

To date, Das has presented research findings at various scientific conferences as “Young Investigator” including the annual scientific meetings of American Society of Anesthesiologists meeting (ASA; October 19-20, 2019 & October 14, 2018), the Australian Pain Society (APS), the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT), the Australasian Pharmaceutical Science Association (APSA) and the Special Interest Group of the International Association for the Study of Pain (NeuPSIG).
2010: Ph.D. scholarship (Australian Postgraduate Award).
2011: Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists travel award.
2011: Australasian Pharmaceutical Science Association travel award.
2012: Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists- Australasian Pharmaceutical Science Association travel award.
2012: Finalist for poster prize at the joint annual scientific meeting of Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists- Australasian Pharmaceutical Science Association, Sydney, Dec 2012.
2013: Australian Pain Society, Ph.D. student travel award.
2013: Spinifex Pharmaceuticals travel award for 4th International Congress on Neuropathic Pain (Special Interest Group) conference in Toronto.
2013: The University of Queensland science faculty grants to build prototype for cold allodynia device.
2013: The University of Queensland Research Scholar Scholarship Award.
2018: American Society of Anesthesiologists, Young Investigator Award for Basic Science at American Society of Anesthesiologist Annual Meeting, October 14th, 2018.
2019: American Society of Anesthesiologists Young Investigator Award for Basic Science at American Society of Anesthesiologists Annual Meeting, October 19th, 2019.
2020: Cohn Fellowship Award (April 2020-June 2021)
2020: American Society of Anesthesiologists Young Investigator Award for Basic Science at American Society of Anesthesiologists Annual Meeting
2020: Schweppe Foundation Award and Armour Bequest Award
2021: American Society of Anesthesiologists, Best of Abstracts: Basic Science
2021-2022 (Schweppe Foundation): Ketamine Metabolite, (2R, 6R) - Hydroxynorketamine as an Alternative Analgesic Target in Low Back Pain, Evaluation of Direct and Indirect Analgesic Efficacy in a Murine Low Back Pain Model.

2020-2021 (Cohn Fellowship): Das' Cohn research will expand to assess the pain-relieving efficiency and mechanisms of AMPK activators in peripheral tissue injury pain. One immediate outcome of this research will be much-needed pharmacological understanding of AMPK activators for low back pain and post-surgical pain.

2019-2021 (RO-1 supplement for the Burn’s R01AT009680-01A1 grant): New Non-Opioid Treatments for Acute and Chronic Pain: Mechanism of the Analgesic Effect of the Ketamine Metabolite, (2R,6R)-Hydroxynorketamine. From this support, we will determine if the analgesic effect of (2R,6R)-HNK injection is associated with differences in glutamate ionotropic receptor AMPA type subunits 1 and 2 (GluA1), (GluA2), brain-derived neurotropic factor (BDNF), and mechanistic target of rapamycin (mTOR) in hippocampus and prefrontal cortex brain slices using Western Blot (WB) analysis in 4 validated models of pain. Role (Co-Investigator): Vaskar Das, Ph.D.

Main Section
- Colleges
- For Professionals
- For Students
- Resources
  - Alumni
  - Get Directions
  - News & Events
  - Cookie Settings
(312) 942-7100
Rush University
600 S. Paulina St.
Chicago, Illinois 60612

Contact Us

Accessibility, Privacy & Harassment Policies

© 2025 Rush University